Molecular breast imaging (MBI) is a nuclear medicine test that uses a small amount of radioactive tracer injected into your bloodstream to detect breast cancer. Unlike mammography, which creates an image based on breast tissue density, MBI highlights areas of increased cellular activity, making it particularly useful for finding cancers that mammograms can miss in women with dense breast tissue.
How MBI Works
Before the scan, you receive an injection of a radiotracer called Technetium-99m sestamibi into a vein in your arm. This compound travels through your bloodstream and accumulates in cells that are metabolically active. Cancer cells take up significantly more of the tracer than normal breast tissue because of their higher metabolic rate. A specialized gamma camera then captures images showing where the tracer has concentrated, revealing abnormal areas that may indicate a tumor.
This approach is fundamentally different from mammography, which works by passing X-rays through the breast and measuring how much tissue blocks the beam. In dense breasts, normal fibrous and glandular tissue can obscure a tumor on a mammogram because both the tumor and the surrounding tissue look white on the image. MBI sidesteps this problem entirely. It doesn’t care about the physical density of the tissue; it detects the biological behavior of cells. A small, fast-growing cancer lights up on an MBI scan regardless of how dense the surrounding breast tissue is.
What the Procedure Feels Like
The experience is straightforward. After the tracer injection, you wait about three to five minutes for it to distribute into your breast tissue. You then sit in a chair with each breast gently compressed between two small gamma camera detectors, similar in concept to mammographic compression but typically described as less intense. The scan itself takes 20 to 40 minutes total for both breasts.
There’s no need for contrast dye, no enclosed tube like an MRI, and no IV line running throughout the procedure. You sit upright rather than lying face down. For women who are claustrophobic or who have implanted devices that prevent them from getting an MRI, these practical differences matter.
Who Benefits Most From MBI
MBI is primarily discussed as a supplemental screening tool for women with dense breast tissue. About half of women undergoing mammography have dense breasts, and this density meaningfully reduces mammography’s ability to find cancer. In clinical trials where mammography was directly compared against other imaging in women with dense breasts, mammography’s sensitivity dropped to 25 to 50 percent. That means mammography missed half or more of the cancers present in these women.
When MBI was added as a supplemental screen after mammography in these populations, it detected an additional 7.7 cancers per 1,000 women screened in one large community practice review. The rate at which MBI findings led to biopsy that confirmed cancer (the positive predictive value) ranged from 28 to 33 percent in prospective trials, which is a reasonably efficient ratio, meaning most biopsies prompted by MBI findings were not false alarms.
MBI is also considered for women at elevated breast cancer risk who cannot undergo breast MRI. This includes women with certain metal implants, severe kidney problems that prevent the use of MRI contrast agents, or significant claustrophobia.
How Small a Cancer MBI Can Find
Modern dedicated gamma cameras used for MBI can identify tumors as small as 2 to 3 millimeters, according to the American College of Radiology. This represents a major improvement over older nuclear breast imaging systems, which were limited to detecting larger masses. The ability to catch cancers at this size is comparable to breast MRI and far exceeds what standard mammography reliably detects in dense tissue.
Radiation Dose
Because MBI involves a radioactive tracer, the radiation exposure is higher than a standard mammogram. The current effective dose for an MBI exam is approximately 2 millisieverts (mSv), roughly four times the dose of a standard 2D mammogram (about 0.5 mSv). This has been one of the main concerns limiting broader adoption of MBI for routine screening.
However, the dose has been falling. Newer protocols at some centers have reduced the administered tracer to a level that delivers less than 1 mSv, putting it much closer to mammography. The Mayo Clinic, which has been one of the leading institutions studying MBI, reports actual administered doses that deliver about 1.9 mSv per exam. Further dose reduction research is ongoing, and some modified systems can now operate at doses under 1 mSv while maintaining image quality.
How MBI Compares to Breast MRI
Breast MRI has been the established supplemental screening tool for high-risk women for years, and it has excellent sensitivity for detecting breast cancer. MBI offers comparable sensitivity for small lesions while differing in several practical ways.
MBI is generally less expensive than breast MRI. The equipment is smaller and more widely deployable, and the exam doesn’t require the specialized MRI-compatible setup or contrast agents that breast MRI demands. MBI also tends to be better tolerated: you sit upright in a chair rather than lying prone in a narrow tube, and the exam is shorter. For women who can’t tolerate or access MRI, MBI fills an important gap.
On the other hand, MBI involves ionizing radiation while MRI does not. Breast MRI also has a longer track record in clinical guidelines and more extensive data supporting its use in high-risk screening. The choice between them often comes down to individual circumstances: your risk level, breast density, ability to undergo MRI, and what your imaging center offers.
Current Guideline Status
Despite promising detection data, MBI has not yet achieved broad endorsement as a routine screening tool. The American College of Radiology currently rates MBI as “usually not appropriate” for supplemental screening across all risk levels and breast density categories. The reasoning centers on several factors: the radiation dose (though this is decreasing), limited large-scale data on screening outcomes like mortality reduction, longer exam times compared to mammography, and relatively few studies spanning the full range of breast densities and risk profiles.
This doesn’t mean MBI is ineffective. It means the evidence base hasn’t yet reached the threshold that guideline committees require to recommend it broadly. In practice, many breast imaging centers do offer MBI, particularly for women with dense breasts who are unable to get breast MRI. Some state breast density notification laws have also increased interest in supplemental screening options like MBI, even as guidelines remain cautious.
Preparation and Practical Details
Some centers ask you to fast for several hours before MBI, because blood sugar levels can affect tracer uptake. You should let your care team know if you’re pregnant or breastfeeding, as the exam involves ionizing radiation. No special clothing is required, though you’ll change into a gown for the scan.
The tracer leaves your body naturally through your urine over the hours following the exam. Side effects from the injection are rare. Most women describe the experience as uneventful, with the main inconvenience being the length of the scan compared to a quick mammogram.
If MBI detects an area of increased tracer uptake, the next step is typically a targeted ultrasound or biopsy to determine whether the finding is cancerous. In the prospective trials studying MBI, about 6 to 8 percent of women were called back for additional evaluation based on MBI findings, a recall rate considerably lower than older nuclear breast imaging techniques, which recalled up to 25 percent of patients.